Simon Spohn

154 posts

Simon Spohn

Simon Spohn

@Simon_Spohn

Resident Radiation Oncology and Clinician Scientist @Uniklinik_Fr. Passionate about #GU cancers and imaging. Views are my own. @ESTRO_RT @degro_ev

Freiburg im Breisgau Katılım Ekim 2010
564 Takip Edilen505 Takipçiler
Simon Spohn
Simon Spohn@Simon_Spohn·
Excited to share our new paper on intrafractional fiducial-based image guidance for focal dose-escalated SBRT in PCa now in PHIRO. This approach easily boosts precision & efficacy for linac-based SBRT in prostate cancer! Check full paper here: sciencedirect.com/science/articl… @ESTRO_RT
English
0
0
2
257
Simon Spohn
Simon Spohn@Simon_Spohn·
So proud of residents @SLBuerkle & Philipp Waibel for presenting at #EMUC25 in Prague 🙌 Their fantastic work earned a Highly Rated Abstract ribbon👌🏻! Great to see them representing our centre from Freiburg & Radiation Oncology with enthusiasm and quality.
Simon Spohn tweet mediaSimon Spohn tweet media
English
5
1
7
598
Simon Spohn
Simon Spohn@Simon_Spohn·
#EMUC25 in #Prague once again is a Highlight for everyone involved in #GU oncology. Excellent organization, high-level interdisciplinary scientific exchange and very instructive case discussions 🙌 @Uroweb @ESTRO_RT
Simon Spohn tweet mediaSimon Spohn tweet media
English
1
4
12
1.9K
Simon Spohn
Simon Spohn@Simon_Spohn·
Honored to join “Rising Stars in Oncology” at the Federal Ministry in Berlin 🇩🇪 representing UKF & Radiation Oncology. Minister Bär highlighted the need to strengthen top-level cancer research in Germany. 💡 #Oncology #CancerResearch #Networking
Simon Spohn tweet mediaSimon Spohn tweet media
English
0
0
7
769
Simon Spohn
Simon Spohn@Simon_Spohn·
Great to be part of the annual German/Swiss/Austrian Oncology Congress #DGHO25 in Cologne 🇩🇪 — sharing insights on SBRT in oligometastatic #ProstateCancer. Inspiring discussions showing how multidisciplinary collaboration continues to shape the future of cancer care! 💡💬
Simon Spohn tweet media
English
1
0
3
483
Simon Spohn
Simon Spohn@Simon_Spohn·
Leopoldina Symposium: AI & tech in medicine in the Focus. 🇩🇪 Debating Germany’s role as a research hub, regulatory updates & fostering innovation. Cross-sector exchange between medicine, science, industry & policy to drive future-ready clinical research. @Leopoldina @AncaGrosu1
Simon Spohn tweet mediaSimon Spohn tweet mediaSimon Spohn tweet media
English
0
1
3
160
Simon Spohn retweetledi
Priyamvada Maitre
Priyamvada Maitre@docpriyamvada·
1st POSITIVE RCT in the #ASTRO2025 Plenary today! #BART meets primary EP of LRFS in High risk MIBC!!!
Priyamvada Maitre tweet mediaPriyamvada Maitre tweet mediaPriyamvada Maitre tweet mediaPriyamvada Maitre tweet media
English
5
27
103
7.8K
Simon Spohn retweetledi
Alison Tree 💙
Alison Tree 💙@alison_tree·
This is big news 👇 No benefit to prophylactic nodal irradiation in NRG/RTOG 0924
Daniel E Spratt@DrSpratticus

#astro25 @NRGonc Rtog 0924 trial on 2500 patients testing whole pelvic RT. Negative trial -OS no difference -PCSM no difference -DM no difference -BCR was not SS different with only 4% difference at 10 years. -toxicity increased 3 cooperative group trials now negative: getug01, Rtog 9413, Rtog 0924. Goodbye WPRT

English
3
9
37
4.7K
Simon Spohn retweetledi
Advanced Prostate Cancer Consensus Conference
Duration of Androgen Suppression with Postoperative Radiotherapy (DADSPORT) for Nonmetastatic Prostate Cancer: A Collaborative Systematic Review and Meta-analysis of Aggregate Data sciencedirect.com/science/articl… This systematic review and meta-analysis by the DADSPORT Collaboration evaluated the impact of hormone therapy (HT) added to postoperative radiotherapy (RT) in nonmetastatic #ProstateCancer across five randomized controlled trials involving 4,411 participants. While HT did not significantly improve overall survival (OS) in the general population, it did show meaningful benefits in metastasis-free survival (MFS) and prostate cancer–specific survival (PCSS), each with a 4% absolute improvement at 8 years. Notably, OS benefits may be limited to patients with higher pre-RT PSA levels or CAPRA-S scores. These findings support the use of adjuvant HT to improve cancer outcomes, particularly in higher-risk patients. @DrSpratticus @AmarUKishan @drjefstathiou @PCaParker @_APollack @PaulSargos @felixfengmd @OncoAlert @Silke_Gillessen @AOmlin @nataliagandur @bavilima
Advanced Prostate Cancer Consensus Conference tweet media
English
1
70
132
15.2K
Simon Spohn retweetledi
Constantinos Zamboglou
Constantinos Zamboglou@CZamboglou·
Great to see many enthusiastic colleagues at our Co-IMPACT meeting. Thanks to all for coming and bringing this huge project forward! #ESTRO2025
Constantinos Zamboglou tweet media
English
0
10
34
2.3K
Simon Spohn
Simon Spohn@Simon_Spohn·
Excited to be part of the #EAU25 in Madrid! It’s an honor to give a presentstion at the Hands-on Training Course on „PSMA PET in guiding local treatment and MDT“Looking forward to exchange knowledge with colleagues and improving interdisciplinary patient care. @Uroweb @ESTRO_RT
Simon Spohn tweet media
English
0
0
10
265
Simon Spohn retweetledi